An arginase-1 SNP that protects against the development of pulmonary hypertension in bronchopulmonary dysplasia enhances NO-mediated apoptosis in lymphocytes
Open Access
- 28 November 2016
- journal article
- research article
- Published by Wiley in Physiological Reports
- Vol. 4 (22) , e13041
Abstract
Arginase and nitric oxide synthase (NOS) share a common substrate, l‐arginine, and have opposing effects on vascular remodeling. Arginase is the first step in polyamine and proline synthesis necessary for cellular proliferation, while NO produced from NOS promotes apoptosis. Previously, we identified a single nucleotide polymorphism (SNP) in the arginase‐1 (ARG1) gene, rs2781666 (T‐allele) that was associated with a decreased risk for developing pulmonary hypertension (PH) in a cohort of infants with bronchopulmonary dysplasia (BPD). In this study, we utilized lymphocytes from neonates (the only readily available cells from these patients expressing the two genotypes of interest) with either the rs2781666 SNP (TT) or wild type (GG) to test the hypothesis that the protection of the ARG1 SNP against the development of PH in BPD would involve augmented NO production leading to more apoptosis. Lymphocytes were stimulated with IL‐4, IL‐13, and phorbol myristate acetate (PMA). We found that TT lymphocytes had similar levels of arginase I and arginase II expression, but there was a tendency for lower urea production (a surrogate marker of arginase activity), than in the GG lymphocytes. The TT lymphocytes also had significantly greater NO production than did GG lymphocytes despite no differences in iNOS expression between genotypes. Furthermore, the TT lymphocytes had lower numbers of viable cells, and higher levels of cleaved caspase‐3 than did GG lymphocytes. Inhibiting NOS activity using Nω‐Nitro‐l‐arginine methyl ester hydrochloride (l‐NAME) significantly decreased cleaved caspase‐3 levels in the TT lymphocytes. These data demonstrate that the TT genotype results in greater levels of NO production leading to more apoptosis, which is consistent with the concept that BPD patients with the TT genotype are protected against the development of PH by producing greater basal levels of endogenous NO.Keywords
Funding Information
- Center for Clinical and Translational Research at The Research Institute, Nationwide Children's Hospital (UL1TR001070)
This publication has 30 references indexed in Scilit:
- Arginases and arginine deficiency syndromesCurrent Opinion in Clinical Nutrition and Metabolic Care, 2012
- Hypoxia-induced proliferation of human pulmonary microvascular endothelial cells depends on epidermal growth factor receptor tyrosine kinase activationAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2010
- Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginaseAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Recent advances in arginine metabolism: roles and regulation of the arginasesBritish Journal of Pharmacology, 2009
- Knockdown of Arginase I Restores NO Signaling in the Vasculature of Old RatsHypertension, 2006
- Gene transfer with inducible nitric oxide synthase decreases production of urea by arginase in pulmonary arterial endothelial cellsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertensionThe FASEB Journal, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Nitric oxide (NO): an effector of apoptosisCell Death & Differentiation, 1999
- Nitric Oxide Induces Upregulation of Fas and Apoptosis in Vascular Smooth MuscleHypertension, 1996